Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.

Br J Cancer · 2010 · PMC2813739 · PMID 19920817

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an overall trendno p-value reported

The average adverse event management costs varied across these countries but showed an overall trend of consistently lower costs for bevacizumab plus IFN versus sunitinib.

also in 4,871 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.